Cullinan Oncology
CGEM
82 hedge funds and large institutions have $386M invested in Cullinan Oncology in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 30 reducing their positions, and 5 closing their positions.
179% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $490K
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
9% more funds holding
Funds holding: 75 → 82 (+7)
0.62% less ownership
Funds ownership: 83.28% → 82.66% (-0.62%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
27% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 30
31% less capital invested
Capital invested by funds: $559M → $386M (-$173M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.31M |
| 2 |
CA
CHI Advisors
New York
|
+$3.73M |
| 3 |
Morgan Stanley
New York
|
+$2.28M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.39M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$2.03M |
| 3 |
O
OrbiMed
New York
|
-$1.81M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.27M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.2M |
CGEM Hedge Fund Activity: Q1 2022 in Review
82 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2022, worth a combined $386M — down 31% from $559M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CGEM positions and 5 closed out — a net gain of 7 holders — while 22 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $9.31M. The largest seller was Deerfield Management, cutting an estimated $4M.
- 82 institutional investors held Cullinan Oncology (CGEM) as of Q1 2022, up from 75 in Q4 2021.
- Funds reported $386M of Cullinan Oncology stock for Q1 2022, down 31% quarter-over-quarter.
- 12 funds opened new Cullinan Oncology positions in Q1 2022 and 5 closed out, a net change of +7 holders.
- The largest Cullinan Oncology buyer in Q1 2022 was Fidelity Investments, an estimated $9.31M added.
- The largest Cullinan Oncology seller in Q1 2022 was Deerfield Management, an estimated $4M sold.
Based on aggregated 13F filings for Q1 2022.